Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.

Published byDevi Pranoto Modified over 5 years ago

Similar presentations

Presentation on theme: "Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis."— Presentation transcript:

1 Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl by Srdan Verstovsek, James P. Dean, Paul Cernohous, Rami S Komrokji, John F. Seymour, Ruben A. Mesa, Mary S Campbell, Susan E. Caldwell, Lixia Wang, and Han Myint Blood Volume 122(21): November 15, 2013 ©2013 by American Society of Hematology

2 Spleen Response by MRI in All Patients.
James P. Dean et al. Blood 2013;122:395 ©2013 by American Society of Hematology

3 ≥35% REDUCTION IN SPLEEN VOLUME FROM BASELINE BY MRI (EVALUABLE POPULATION with MF).
James P. Dean et al. Blood 2013;122:395 ©2013 by American Society of Hematology

Download ppt "Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis."

Similar presentations

Verstovsek S et al. Proc ASCO 2011;Abstract 6500.

Verstovsek S et al. Proc ASCO 2011;Abstract 6500.
Ongoing clinical trials with JAK2 inhibitors in MF

Ongoing clinical trials with JAK2 inhibitors in MF
Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA JAK.

Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA JAK.
Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Therapy.

Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Therapy.
Results of a Randomized Study of the JAK Inhibitor Ruxolitinib (INC424) versus Best Available Therapy (BAT) in Primary Myelofibrosis (PMF), Post- Polycythemia.

Results of a Randomized Study of the JAK Inhibitor Ruxolitinib (INC424) versus Best Available Therapy (BAT) in Primary Myelofibrosis (PMF), Post- Polycythemia.
Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post- Essential.

Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post- Essential.
Efficacy, Hematologic Effects and Dose of Ruxolitinib in Myelofibrosis Patients with Low Platelet Starting Counts (50-100 x 10 9 /L): A Comparison to Patients.

Efficacy, Hematologic Effects and Dose of Ruxolitinib in Myelofibrosis Patients with Low Platelet Starting Counts ( x 10 9 /L): A Comparison to Patients.
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study by David M.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study by David M.
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.
Interim Results from a Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation.

Interim Results from a Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation.
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
Verstovsek S et al. Proc ASH 2011;Abstract 793.

Verstovsek S et al. Proc ASH 2011;Abstract 793.
Harrison CN et al. Proc ASH 2015;Abstract 59.

Harrison CN et al. Proc ASH 2015;Abstract 59.
PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy CCO Independent Conference Highlights of the 2015 ASCO.

PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy CCO Independent Conference Highlights of the 2015 ASCO.
New Findings in Hematology: Independent Conference Coverage

New Findings in Hematology: Independent Conference Coverage
Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.

Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Similar presentations

Ads by Google